Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?

Clinical and Translational Oncology

Volumn 13, Issue 7, 2011, Pages 451-459

  Gordoa, Teresa Alonso ^a   García Sáenz, José Ángel ^a   Moreno, Juan Francisco Rodríguez ^a   Pérez, Francisco José Hernández ^b   Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Breast cancer; Cardiotoxicity; Reversibility; Trastuzumab

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CARVEDILOL; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; PLACEBO; TRASTUZUMAB; TROPONIN I; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PATIENT MONITORING; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSIBILITY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; HEART DISEASE; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEART DISEASES; HUMANS; PROGNOSIS;

EID: 82255169612     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0682-1     Document Type: Article

References (31)

1. Fiuza M (2009) Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Ther 26:S9-17
2. Chen MH, Kerkela R, Force T (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118:84-95
3. Bria E, Cuppone F, Milella M et al (2008) Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Exp Opin Biol Ther 8: 1963-1971
4. Force T, Krause DS, Van Ette RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344 (Pubitemid 46652481)
5. Guglin M, Cutro R, Mishkin JD (2008) Trastuzumab-induced cardiomyopathy. J Card Fail 14:437-444 (Pubitemid 351749842)
6. Ewer MS, O'Shaughnessy JA (2007) Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 7:600-607 (Pubitemid 47028508)
7. Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459-467 (Pubitemid 351695459)
8. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
9. Chien AJ, Rugo HS (2010) The cardiac safety of trastuzumab in the treatment of breast cancer. Exp Opin Drug Saf 9:335-346
10. Procter M, Suter TM, de Azambuja E et al (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28:3422-3428
11. Russell SD, Blackwell KL, Lawrence J et al (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28:3416-3421
12. Costa RB, Kurra G, Greenberg L et al (2010) Efficacy and cardiac safety of adjuvant trastuzumabbased chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21:2153-2160
13. Albini A, Pennesi G, Donatelli F et al (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102:14-25
14. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M (2009) Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 4:77-88
15. Perik PJ, de Korte MA, van Veldhuisen DJ et al (2007) Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Exp Rev Anticancer Ther 7:1763-1771 (Pubitemid 350303006)
16. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231-2247
17. Sengupta PP, Northfelt DW, Gentile F et al (2008) Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 83:197-203 (Pubitemid 351303103)
18. Cardinale D, Sandri MT, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517-522
19. Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing highdose chemotherapy. Circulation 109:2749-2754 (Pubitemid 38737923)
20. Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481 (Pubitemid 44901520)
21. Granger CB (2006) Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? Circulation 114:2432-2433 (Pubitemid 44901514)
22. Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J Am Coll Cardiol 48: 2258-2262 (Pubitemid 44855419)
23. Martin M, Esteva FJ, Alba E et al (2009) Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 14:1-11
24. Murray LJ, Ramakrishnan S, O'Toole L et al (2010) Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. Breast 19:339-344
25. Yeh ET, Tong AT, Lenihan DJ et al (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109:3122-3131
26. Ewer MS, Lenihan DJ (2008) Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 26:1201-1203
27. Nousiainen T, Vanninen E, Jantunen E et al (2002) Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251:228-234 (Pubitemid 34227187)
28. Cardinale D, Colombo A, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910-3916
29. Ewer MS, Vooletich MT, Durand JB et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820-7826 (Pubitemid 46657379)
30. Hong RA, Iimura T, Sumida KN, Eager RM (2010) Cardio-oncology/onco- cardiology. Clin Cardiol 33:733-737
31. Seidman A, Hudis C, Pierri MK (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221 (Pubitemid 34177427)